← Back to Search

Antidepressant

Tailored intervention for Nicotine Addiction

Phase 3
Waitlist Available
Led By Mark W. Vander Weg, Ph.D.
Research Sponsored by Mark Vander Weg
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up six-month follow-up
Awards & highlights

Study Summary

The project is designed to examine the effectiveness of strategies to increase access to treatment for tobacco use and dependence among rural Veteran smokers. In addition, it will examine whether tailored treatment that is designed to address common comorbid conditions that are related to cigarette smoking enhances success with quitting relative to enhanced standard of care. The investigators hypothesize that participants assigned to the tailored tobacco cessation intervention will report greater cessation rates at six months. The investigators also anticipate more favorable outcomes on measures of depressive symptoms, alcohol use, and body weight.

Eligible Conditions
  • Nicotine Addiction
  • Tobacco Use

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~six-month follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and six-month follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Tobacco use
Secondary outcome measures
Alcohol use
Body weight
Depressive symptoms
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Tailored interventionExperimental Treatment12 Interventions
Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.
Group II: Enhanced standard of careActive Control9 Interventions
Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupropion
FDA approved
Varenicline
FDA approved
Tailored behavioral intervention
2012
Completed Phase 2
~70
Alcohol use risk reduction
2012
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentFED
1,612 Previous Clinical Trials
3,305,332 Total Patients Enrolled
Mark Vander WegLead Sponsor
2 Previous Clinical Trials
262 Total Patients Enrolled
Mark W. Vander Weg, Ph.D.Principal InvestigatorVRHRC-CR

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers
Mark Vander Weg 2013. "Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01892813.
All > Wellbutrin
~35 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top